Design: prespecified mortality analysis of a double-blind, randomised, placebo-controlled trial
Population: 12,257 adults with atherosclerosis or high-risk diabetes, no prior myocardial infarction or stroke, LDL ≥90 mg/dL
Primary outcome: all-cause mortality and cause-specific death over median 4.6 years
Effect: all-cause death HR 0.80 (95% CI 0.70–0.91), 5-year rates 7.9% vs 9.7%; CV death HR 0.79 (0.64–0.98)

VESALIUS-CV enrolled 12,257 patients (median age 66, 43% women) with qualifying atherosclerosis or high-risk diabetes, no previous myocardial infarction or stroke, and LDL cholesterol at least 90 mg/dL (or non-HDL at least 120, or apolipoprotein B at least 80), randomised double-blind to evolocumab or placebo. This prespecified analysis reports the mortality outcomes.

Over a median 4.6 years, 973 patients (7.9%) died. All-cause mortality was 20% lower with evolocumab: 434 deaths, 5-year Kaplan-Meier rate 7.9%, against 539 deaths and 9.7% on placebo (hazard ratio 0.80, 95% CI 0.70 to 0.91, P = 0.0005). Cardiovascular death was lower (HR 0.79, 0.64 to 0.98), non-cardiovascular death was directionally lower but not conclusive (HR 0.85, 0.71 to 1.01), and deaths of undetermined cause were lower (HR 0.64, 0.45 to 0.92). Benefit was consistent across age, sex, region, race, qualifying condition, baseline LDL and background lipid therapy.

The non-cardiovascular mortality finding is the part that needs care. Multistate modelling suggested 78% of it (bootstrap interquartile range 71 to 92%) was driven by preventing non-fatal myocardial infarction, stroke and ischaemia-driven revascularisation, which themselves raised the risk of dying from something else in the following year. That is a plausible account rather than a demonstrated mechanism, but it does reframe a non-fatal event as a marker of decline rather than an endpoint survived.

For practice, this pushes intensive LDL lowering earlier in the risk trajectory in patients who look well. Cost remains the constraint in India, where PCSK9 inhibitors are not routinely affordable outside a small group.

Identify high-risk primary prevention patients whose LDL stays above 90 mg/dL on maximal tolerated statin and ezetimibe
Include high-risk diabetes without established atherosclerosis in that assessment — benefit was consistent there
Discuss cost and duration explicitly before starting; this is a long-term commitment
Do not treat a non-fatal infarct as an event the patient has simply got past — the following year carries risk

Why it matters

It challenges the habit of reserving the most intensive lipid lowering for patients who have already had an infarct.

The statistics, in plain English

A hazard ratio of 0.80 with a confidence interval of 0.70 to 0.91 excludes 1.0, so the mortality reduction is unlikely to be chance. The non-cardiovascular death interval of 0.71 to 1.01 just includes 1.0 — compatible with no effect, and it should be described as directional rather than established. Absolute terms matter here: 7.9% versus 9.7% at five years is about 18 deaths avoided per 1,000 patients treated.